management of thrombosis risk with ponatinib and other tkis for cml?
Published 9 years ago • 1.2K plays • Length 24:30Download video MP4
Download video MP3
Similar videos
-
2:49
outcomes of patients with cml-cp treated with ponatinib vs 2g-tkis in the third-line setting
-
21:44
how should chronic-phase cml management be influenced by rt-pcr results at 3 months
-
20:24
chronic myeloid leukemia: approaches to optimizing care in the era of tkis
-
21:14
cml molecular monitoring: practical advice
-
17:31
debate: chronic-phase cml patient develops a t315i mutation - experimental therapy
-
5:03
role of ponatinib in treatment of r/r cml
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
21:32
who should still be transplanted for cml in 2015?
-
8:00
dr. cortes discusses approval of ponatinib for adults with chronic-phase cml
-
5:07
case 2: ponatinib for t315i-mutated cml
-
5:22
bosutinib versus ponatinib in r/r cml
-
2:11
addressing the issue of resistance to tkis in cml
-
3:20
thrombosis, myelofibrosis, and acute myeloid leukemia
-
8:12
treatment selection for resistant or intolerant chronic myeloid leukemia
-
1:35
safety of ponatinib in chronic-phase chronic myeloid leukemia (cml) patients
-
7:42
ponatinib: promises and challenges
-
7:47
is ponatinib safe for treating cml?
-
21:13
chronic myelomonocytic leukemia (cmml): diagnosis and therapy